TI
GBT

tru Independence’s Global Blood Therapeutics, Inc. GBT Stock Holding History

tru Independence’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$17.3K – 761
2020
Q4 		$17.3K Buy
+400
New +$19.7K 0.03% 215

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

tru Independence's GBT Position: Q1 2021 in Review

tru Independence sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 400 shares — an estimated $17.3K sold.

tru Independence first reported a position in GBT in Q4 2020 and held it in 1 quarter. The position peaked at $17.3K in Q4 2020. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

  • tru Independence reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • tru Independence sold 400 Global Blood Therapeutics, Inc. shares in Q1 2021, an estimated $17.3K.
  • tru Independence first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 1 quarter.
  • tru Independence's Global Blood Therapeutics, Inc. position peaked at $17.3K in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on tru Independence's 13F filing for Q1 2021, filed 20 May 2021.